AstraZeneca (LSE:AZN) recently reported a 1.9% decline in its share price over the last week. This movement coincides with ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the DESTINY-Breast09 Phase 3 trial of Enhertu (5.4mg/kg) ...

Hiroyuki Okuzawa, CEO of Japanese pharmaceutical giant Daiichi Sankyo, talks about the company's revenue driver in its latest report, and the lack of visibility from the impact of potential U.S.

AstraZeneca's Enhertu shows significant success in late-stage trials as a first-line treatment for HER2-positive metastatic ...

The Delhi High Court is reviewing RHC Healthcare's challenge to the 'Fortis' trademark sale to Fortis Healthcare, alleging ...

Springtime in Washington, D.C., is synonymous with cherry blossom season, when the thousands of cherry blossom trees gifted ...

Analysts at Leerink Partners said in a Monday note that DESTIN-Breast09’s findings “could support an approval” for Enhertu in ...

Daiichi Sankyo seeks Japanese approval for Enhertu to treat patients with HER2 positive metastatic solid tumours: Tokyo Friday, April 25, 2025, 09:00 Hrs [IST] Daiichi Sankyo has ...

Investing.com -- Daiichi Sankyo Co., Ltd. (TSE:TYO: 4568) shares surged 6.2% after the pharmaceutical company announced robust fourth-quarter earnings that surpassed expectations, coupled with a ...

Thank you for waiting. Now we would like to begin Daiichi Sankyo's Financial Results Conference on FY2024. I am Asakura from Corporate Communications. I am your moderator today. We will be using ...

Donna McMenamin is one of thousands of breast cancer patients in the UK caught up in a disagreement over costs between the ...

A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer has interim clinical data showing it helped patients ...